1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Greece Pharmaceuticals and Healthcare Report Q1 2017

Greece Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 81 pages

Includes 3 FREE quarterly updates


>BMI View:
Drugmakers will continue to face challenges in Greece due to the country's poor governance of the pharmaceutical market. The brunt of this has been felt by patients, with widespread medicine shortages, and also by pharmaceutical firms, with rising healthcare provider debts, aggressive medicine pricing policies and challenging pharmaceutical expenditure policies. We maintain our view that in the short- to medium-term, the Greek pharmaceutical market will remain an unattractive investment proposition.

Headline Expenditure Projections

- Pharmaceuticals: EUR4.95bn (USD5.48bn) in 2015 to EUR4.98bn (USD5.33bn) in 2015, 0.7% in local currency terms and -2.8% in US dollar terms. Forecast downgraded from previous quarter.

- Healthcare: EUR13.88bn (USD15.40bn) in 2015 to EUR14.01bn (USD14.99bn) in 2016, 0.9% in local currency terms and -2.7% in US dollar terms. Forecast unchanged from previous quarter. In BMI's Q117 Pharmaceutical Risk/Reward Index (RRI) Greece is ranked second out of the 21 markets in the Central and Eastern European (CEE) matrix despite a significantly reduced score of 60.6 compared with the previous quarter (61.8). This decrease is a result of a downgrade of our USD/EUR exchange rate forecast by BMI's Country Risk team, resulting in a significantly lower Sector Value Growth metric score (measured in USD).

Table Of Contents

Greece Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Greece 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Greece 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Greece 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Greece 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Greece 2012-2020) 16
Prescription Drug Market Forecast 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Greece 2012-2020) 18
Patented Drug Market Forecast 19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Greece 2012-2020) 20
Generic Drug Market Forecast 21
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Greece 2012-2020) 22
OTC Drug Market Forecast 23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Greece 2012-2020) 24
Pharmaceutical Trade Forecast 25
Table: Pharmaceutical Trade Data And Forecasts (Greece 2014-2020) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Greece 2014-2020) 27
Industry Risk/Reward Index 28
Central And Eastern Europe Risk/Reward Index - Q1 2017 28
Greece Risk/Reward Index 35
Rewards 35
Risks 36
Regulatory Review 37
Intellectual Property Issues 40
Pricing Regime 41
Reimbursement Regime 42
Market Overview 44
Healthcare Sector 44
Table: Healthcare Resources (Greece 2010-2015) 47
Table: Healthcare Personnel (Greece 2010-2015) 47
Table: Healthcare Activity (Greece 2010-2015) 48
Research and Development 48
Clinical Trials 49
Epidemiology 50
Competitive Landscape 52
Research-Based Industry 52
Table: Multinational Market Activity 54
Pharmaceutical Distribution 56
Pharmaceutical Retail Sector 56
Company Profile 58
Elpen 58
Genesis Pharma 60
Kleva 62
Lavipharm 64
Pharmathen 66
Vianex 68
Demographic Data 70
Demographic Forecast 70
Table: Population Headline Indicators (Greece 1990-2025) 71
Table: Key Population Ratios (Greece 1990-2025) 71
Table: Urban/Rural Population and Life Expectancy (Greece 1990-2025) 72
Table: Population By Age Group (Greece 1990-2025) 72
Table: Population By Age Group % (Greece 1990-2025) 73
Glossary 75
Methodology 77
Pharmaceutical Expenditure Forecast Model 77
Healthcare Expenditure Forecast Model 77
Notes On Methodology 78
Risk/Reward Index Methodology 79
Index Overview 80
Table: Pharmaceutical Risk/Reward Index Indicators 80
Indicator Weightings 81

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.